Label Adherence for Non-Vitamin K Antagonist Oral Anticoagulants in a Prospective Cohort of Asian Patients with Atrial Fibrillation
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, So-Ryoung | - |
dc.contributor.author | Lee, Young Soo | - |
dc.contributor.author | Park, Ji-Suck | - |
dc.contributor.author | Cha, Myung-Jin | - |
dc.contributor.author | Kim, Tae-Hoon | - |
dc.contributor.author | Park, Junbeom | - |
dc.contributor.author | Park, Jin-Kyu | - |
dc.contributor.author | Lee, Jung-Myung | - |
dc.contributor.author | Kang, Ki-Woon | - |
dc.contributor.author | Shim, Jaemin | - |
dc.contributor.author | Uhm, Jae-Sun | - |
dc.contributor.author | Kim, Jun | - |
dc.contributor.author | Kim, Changsoo | - |
dc.contributor.author | Kim, Jin-Bae | - |
dc.contributor.author | Park, Hyung Wook | - |
dc.contributor.author | Joung, Boyoung | - |
dc.contributor.author | Choi, Eue-Keun | - |
dc.date.accessioned | 2021-09-01T18:12:47Z | - |
dc.date.available | 2021-09-01T18:12:47Z | - |
dc.date.created | 2021-06-19 | - |
dc.date.issued | 2019-03 | - |
dc.identifier.issn | 0513-5796 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/67179 | - |
dc.description.abstract | Purpose: Label adherence for non-vitamin K antagonist oral anticoagulants (NOACs) has not been well evaluated in Asian patients with non-valvular atrial fibrillation (AF). The present study aimed to assess label adherence for NOACs in a Korean AF population and to determine risk factors of off-label prescriptions of NOACs. Materials and Methods: In this COmparison study of Drugs for symptom control and complication prEvention of AF (CODE-AF) registry, patients with AF who were prescribed NOACs between June 2016 and May 2017 were included. Four NOAC doses were categorized as on- or off-label use according to Korea Food and Drug Regulations. Results: We evaluated 3080 AF patients treated with NOACs (dabigatran 27.2%, rivaroxaban 23.9%, apixaban 36.9%, and edoxaban 12.0%). The mean age was 70.5 +/- 9.2 years; 56.0% were men; and the mean CHA(2)DS(2)-VASc score was 3.3 +/- 1.4. Only one-third of the patients (32.7%) was prescribed a standard dose of NOAC. More than one-third of the study population (n=1122, 36.4%) was prescribed an off-label reduced dose of NOAC. Compared to those with an on-label standard dosing, patients with an off-label reduced dose of NOAC were older (>= 75 years), women, and had a lower body weight (<= 60 kg), renal dysfunction (creatinine clearance <= 50 mL/min), previous stroke, previous bleeding, hypertension, concomitant dronedarone use, and anti-platelet use. Conclusion: In real-world practice, more than one-third of patients with NOAC prescriptions received an off-label reduced dose, which could result in an increased risk of stroke. Considering the high risk of stroke in these patients, on-label use of NOAC is recommended. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | YONSEI UNIV COLL MEDICINE | - |
dc.subject | STROKE PREVENTION | - |
dc.subject | WARFARIN | - |
dc.subject | DABIGATRAN | - |
dc.subject | RIVAROXABAN | - |
dc.subject | MANAGEMENT | - |
dc.subject | SAFETY | - |
dc.subject | RISK | - |
dc.title | Label Adherence for Non-Vitamin K Antagonist Oral Anticoagulants in a Prospective Cohort of Asian Patients with Atrial Fibrillation | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Shim, Jaemin | - |
dc.identifier.doi | 10.3349/ymj.2019.60.3.277 | - |
dc.identifier.scopusid | 2-s2.0-85062076240 | - |
dc.identifier.wosid | 000459544000005 | - |
dc.identifier.bibliographicCitation | YONSEI MEDICAL JOURNAL, v.60, no.3, pp.277 - 284 | - |
dc.relation.isPartOf | YONSEI MEDICAL JOURNAL | - |
dc.citation.title | YONSEI MEDICAL JOURNAL | - |
dc.citation.volume | 60 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 277 | - |
dc.citation.endPage | 284 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART002438179 | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | General & Internal Medicine | - |
dc.relation.journalWebOfScienceCategory | Medicine, General & Internal | - |
dc.subject.keywordPlus | STROKE PREVENTION | - |
dc.subject.keywordPlus | WARFARIN | - |
dc.subject.keywordPlus | DABIGATRAN | - |
dc.subject.keywordPlus | RIVAROXABAN | - |
dc.subject.keywordPlus | MANAGEMENT | - |
dc.subject.keywordPlus | SAFETY | - |
dc.subject.keywordPlus | RISK | - |
dc.subject.keywordAuthor | Atrial fibrillation | - |
dc.subject.keywordAuthor | non-vitamin K antagonist oral anticoagulant | - |
dc.subject.keywordAuthor | drug labeling | - |
dc.subject.keywordAuthor | dose | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.